Royalty Report: Drugs, Cancer, Biotechnology – Collection: 27631

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 16

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16

Primary Industries

  • Drugs
  • Cancer
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27631

License Grant
The Licensee has the exclusive right to develop, manufacture and commercialize Opdivo in all territories worldwide except Japan, South Korea and Taiwan (where the Licensor was responsible for all development and commercialization prior to the amendment). The alliance agreement was amended to provide for additional collaboration activities in Japan, South Korea and Taiwan pertaining to Opdivo and several other Licensee compounds including ipilimumab, lirilumab, urelumab and BMS-986016 (anti-LAG3). Both parties have the right and obligation to jointly develop and commercialize the compounds. The Licensee is responsible for supply of the product.
License Property
The agreement is to develop and commercialize Opdivo, an anti-PD-1 human monoclonal antibody being investigated as an anti-cancer treatment. Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and NKT cells. It is being investigated as an anticancer treatment. It is in Phase III trials (which commenced in 2012) in non-small cell lung cancer, renal cell cancer and melanoma.
Field of Use
The parties jointly own a patent covering Opdivo as a composition of matter that expires in 2027 in the U.S. (excluding potential patent term extension). In December 2014, the FDA approved Opdivo for unresectable (inoperable) or metastatic melanoma, and disease progression following Yervoy and, if BRAF V600 mutation positive, a BRAF inhibitor. Opdivo was also approved in Japan in July 2014 for the same indication. The FDA has granted Fast Track designation for Opdivo in three tumor types non-small cell lung cancer, renal cell carcinoma and metastatic melanoma, and it is in the registrational process for melanoma and non-small cell lung cancer in the U.S. and Europe. The FDA granted Breakthrough Therapy designation for Hodgkin Lymphoma in 2014.

IPSCIO Record ID: 332563

License Grant
The Chinese Licensor and U.S. Licensee, by this collaboration is for the development and commercialization of toripalimab, Licensor’s anti-PD-1 antibody, in the United States and Canada. Upon satisfaction of closing conditions, The Parties will co-develop toripalimab, and Licensee will be responsible for all commercial activities in the licensed territory.

Under the terms of the agreement, Licensee will also be granted options to Licensor’s TIGIT-targeted antibody and next generation engineered IL-2 cytokine for evaluation as potential combination therapies with toripalimab, as well as certain negotiation rights to two early-stage checkpoint inhibitor antibodies.

JS006, an antibody targeting TIGIT.

JS018, a next-generation engineered IL-2 cytokine

Two additional undisclosed early-stage novel immuno-oncology drug candidates.

License Property
Toripalimab is a Chinese domestic anti-PD-1 monoclonal antibody, also approved for the second-line treatment of patients with unresectable or metastatic melanoma, and, supplemental NDAs of toripalimab for the third-line treatment of recurrent/ metastatic nasopharyngeal carcinoma and second-line treatment of metastatic urothelial carcinoma.

JS006 is an antibody targeting TIGIT, a clinically validated immune inhibitory checkpoint. Anti-TIGIT antibodies have demonstrated synergistic anti-tumor activity in combination with anti-PD-1 antibodies.

JS018 is a next-generation engineered IL-2 cytokine designed to inhibit stimulation of regulatory T cells while retaining stimulatory activity on effector T cells and natural killer (“NK”) cells. The option to JS018 is exercisable prior to initiation of Phase 2 clinical development.

Field of Use
This transaction expands Licensees late-stage pipeline into the rapidly growing checkpoint inhibitor market and in oncology with biosimilars.

By this Collaboration, the Parties plan to file additional toripalimab BLAs with the FDA over the next three years for multiple rare and highly prevalent cancers, including non-small cell lung cancer (“NSCLC”).

IPSCIO Record ID: 325366

License Grant
Through a partnership with a third party, Licensee develops and/or commercialize sugemalimab for worldwide sales which results in royalty payments to Licensor.
License Property
Sugemalimab (CS1001), an OmniAb-derived anti-PD-L1 monoclonal antibody used in combination with chemotherapy for lung cancer.
Field of Use
Field of use is for the first-line treatment of advanced squamous and non-squamous non-small cell lung cancer (“NSCLC”).

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. The main subtypes of NSCLC Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

IPSCIO Record ID: 28127

License Grant
The Licensee entered into an exclusive collaboration Agreement with the Licensor, for the development and commercialisation of MEDI4736 across a range of blood cancers including non-Hodgkin''s lymphoma, myelodysplastic syndromes and multiple myeloma.
License Property
MEDI4736 is an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. MEDI4736 blocks these signals, countering the tumour's immune-evading tactics. MEDI4736 was accelerated into Phase III clinical development in non-small cell lung cancer and head and neck cancer. The Licensor will also be responsible for global commercialisation of approved treatments.
Field of Use
The Licensee will manufacture and book all sales of MEDI4736 and will pay a royalty to the Licensor on worldwide sales in haematological indications.

IPSCIO Record ID: 252203

License Grant
The Parties entered into an agreement to obtain a license under certain patents owned and/or exclusively licensed by one or more of those parties that includes the right to develop and sell Libtayo.
License Property
Libtayo® (cemiplimab), an antibody targeting the receptor known as programmed cell death protein 1 (PD-1).

LIBTAYO® is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Cutaneous squamous cell carcinoma (cSCC) is a type of skin cancer.

Field of Use
This agreement pertains to the drug industry relating to antibody-based cancer treatments in the field of immuno-oncology.

IPSCIO Record ID: 192822

License Grant
The Licensee entered into a settlement and license agreement with the Licensor resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as Keytruda. The Licensee will pay royalties on the worldwide sales of Keytruda for a non-exclusive license to market Keytruda in any market in which it is approved.
License Property
anti-PD-1 antibody drug, nivolumab, produceScomplete or partial responses in non-small-cell lung cancer, melanoma, and renal-cell cancer, in a clinical trial with a total of 296 patients.
Field of Use
This agreement pertains to the pharmaceutical industry.  Anti-PD-1 antibody for the treatment of cancer, such as Keytruda.

IPSCIO Record ID: 4661

License Grant
The parties entered into an exclusive license agreement to develop and commercialize lucitanib on a global basis, excluding China.
License Property
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α-ß).
Field of Use
A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. FGFR amplification is common in a number of tumor types, including breast cancer and squamous non-small cell lung cancer, and we intend to study lucitanib in these cancers as well as other solid tumors exhibiting FGFR pathway activation.

IPSCIO Record ID: 306778

License Grant
Licensor (i) assigned to Licensee its patents/patent applications covering XP-102, known as BI 882370, a 2nd-generation pan-RAF inhibitor; and (ii) granted Licensee a worldwide, exclusive, royalty-bearing, and non-transferable license to all know-how controlled by Licensor or affiliates necessary for, or specifically related to, the discovery, development, manufacture, commercialization, or use of XP-102 and any family compound.
License Property
XP-102 is a second generation potent and selective pan-RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase. It is an oral small molecule drug candidate that is being developed for the potential treatment of colorectal cancer, melanoma, non-small cell lung cancer, hairy cell leukemia, and potentially other cancer types.

Licensor focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology.

Field of Use
XP-102 for all human and non-human diagnostic, prophylactic, and therapeutic uses, including therapeutic uses targeting hematological and solid tumors.  It is being developed for the potential treatment of colorectal cancer, melanoma, non-small cell lung cancer, hairy cell leukemia, and potentially other cancer types.

Licensee is a biopharmaceutical company that discovers and develops innovative small molecule drug candidates for the treatment of cancer in humans.

IPSCIO Record ID: 386935

License Grant
The parties collaborated to create and develop bispecific antibodies using Licensor’s DuoBody technology platform.

Under this original agreement, Licensee had the right to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations.

Licensee received approval from the FDA for amivantamab, as RYBREVANT, a therapy that was created using Danish Licensor’s proprietary DuoBody bispecific technology platform.

License Property
Amivantamab has been approved in the United States and the European Union under the name RYBREVANT for the treatment of certain adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with epidermal growth factor receptor (“EGFR”) exon 20 insertion mutations. The two antibody libraries used to produce amivantamab were both generated by Licensor. The antibody pair used to create amivantamab was selected in collaboration between the parties.
Field of Use
The rights grants is used for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. Amivantamab, created using Licensor’s DuoBody technology platform is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets.

IPSCIO Record ID: 135967

License Grant
This amendment includes commercialization rights for cabozantinib in Canada.
License Property
Cobimetinib is a potent, highly selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors.  It is indicated in combination with vemurafenib as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma.  The company is a biopharmaceutical company that discovers, develops and commercializes small molecule therapies for the treatment of cancer.  The business focuses predominantly on the development and commercialization of cabozantinib, an internally-discovered inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is currently approved in the United States and European Union for the treatment of progressive, metastatic medullary thyroid cancer, or MTC, and is marketed under the brand name COMETRIQ®.
Field of Use
The Company is developing its proprietary compound known as cabozantinib for the treatment of cancer, and owns or controls certain patents, know-how and other intellectual property relating to such compound.

IPSCIO Record ID: 367327

License Grant
In consideration of the equity in the Canadian Licensee, the royalty payments reserved herein, and the covenants on the part of the Licensee contained herein, the Canadian University hereby
(a)           grants to the Licensee an exclusive worldwide license to use and sublicense the Technology, any University Improvements and Confidential Information on the terms and conditions hereinafter set forth during the term of this Agreement;  and
(b)           grants to the Licensee an exclusive worldwide license to use and sublicense to manufacture, distribute, have distributed, sell and have sold, Products on the terms and conditions hereinafter set forth during the term of this Agreement.

The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any University Improvements with the prior written consent of the University, which consent shall not be unreasonably refused.

License Property
Technology relating to antisense oligonucleotide therapy for the treatment of prostate cancer and other cancers.

U.S. Provisional filed July 19, 1999 – Serial No. 60/144,495
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone–Regulated Tumors

Full U.S. application flied July 19, 2000 – Serial No. 09/619,908
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

PCT filed July 19, 2000 – Serial No. PCT/CA00/00853
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

Field of Use
Field of use is for the treatment of prostate cancer and other cancers.

OGX-011 is focused on reducing clusterin production to enhance treatment sensitivity and delay tumor progression in patients who have not fully developed treatment resistance and to restore treatment sensitivity in patients who have developed treatment resistance. Clusterin is a cell survival protein that is over-produced in several cancer indications in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration.

IPSCIO Record ID: 26485

License Grant
The Company entered into a licensing agreement with South Africa Licensee with respect to co-development of various RNA drugs, including Ampligen® . The licensing agreement provides Licensee with an exclusive manufacturing and marketing license for certain southern hemisphere countries (including certain countries in South America, Africa and Australia as well as the United Kingdom and Ireland (the licensed territory) .
License Property
Ampligen® is a our proprietary drug to treat diseases for which adequate treatment is not available. We seek the required regulatory approvals which will allow the progressive introduction of Ampligen® for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), HIV, Hepatitis C (“HCV”) and Hepatitis B (“HBV”) in the U.S., Canada, Europe and Japan. Ampligen® is currently in phase III clinical trials in the U.S. for use in treatment of ME/CFS and is in Phase IIb clinical trials in the U.S. for the treatment of newly emerged multi-drug resistant HIV, and for the induction of cell mediated immunity in HIV patients that are under control using potentially toxic drug cocktails.

Our proprietary drug technology Ampligen® utilizes specially configured ribonucleic acid (“RNA”) and is protected by more than 350 patents worldwide with over 80 additional patent applications  pending to provide further proprietary protection in various international markets. Certain patents apply to the use of Ampligen® alone and certain patents apply to the use of Ampligen® in combination with certain other drugs. Some composition of matter patents pertain to other new medications which have a similar mechanism of action. The main U.S. ME/CFS treatment patent (#6130206) expires January 23, 2015. Our main patents covering HIV treatment (#4795744,#4820696, #5063209, and #5091374) expire on August 26, 2006, September 30, 2008, August 10, 2010, respectively; Hepatitis treatment coverage is conveyed by U.S. patent #5593973 which expires on October 15, 2014. The U.S. Ampligen® Trademark (#1,515,099) expires on December 6, 2008 and can be renewed thereafter for an additional 10 years. The U.S. FDA has granted us “orphan drug status” for our nucleic acid-derived therapeutics for ME/CFS, HIV, and renal cell carcinoma and malignant melanoma. Orphan drug status grants the Company protection against competition for a period of seven years following FDA approval, as well as certain federal tax incentives, and other regulatory benefits.

IPSCIO Record ID: 182116

License Grant
The parties entered an agreement for one of the Licensors programs.
License Property
This program is for MM-121 or Seribantumab. Seribantumab is an antibody-drug that targets ErbB3 that was developed using the Selexis SUREtechnology Platform.
Field of Use
Licensee is currently conducting a Phase 2 trial of seribantumab (MM-121) in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer whose disease has progressed following immunotherapy.

IPSCIO Record ID: 25786

License Grant
Licensee received an exclusive worldwide license from the University.  This includes the rights to sublicense and the intellectual property associated with SDX-101 and SDX-102, as well as issued patents and patent applications for several pre-clinical-stage projects, including the SDX-103 program.
License Property
SDX-101 is an oral compound which does not suppress the body’s immune system for the treatment of CLL. SDX-101 is an isomer, or component, of Lodine®, a marketed anti-inflammatory drug. The U.S. Food and Drug Administration, or FDA, has granted orphan drug status, a designation for drugs intended to treat a rare disease or condition affecting no more than 200,000 individuals in the U.S., for SDX-101 for the treatment of CLL.

SDX-102 is an intravenously administered small molecule which laboratory studies have shown kills tumors which cannot produce an important metabolic enzyme. Safety and tolerability data on SDX-102 were collected in clinical trials conducted at academic centers sponsored by the National Cancer Institute, or the NCI. These clinical trials tested the drug across a variety of cancers which are now known to produce this enzyme with a high frequency. The Licensee developed a proprietary, practical laboratory assay, or test, to identify patients whose cancers cannot produce this metabolic enzyme. In 2004, the Licensee was conducting Phase II trials of SDX-102 and are using their assay to select patients for these trials in difficult-to-treat cancers, including non-small cell lung cancer, or NSCLC, pancreatic and mesothelioma, none of which was previously studied by the NCI. The SDX-103 program involves analogs of the compound indanocine. Indanocine and indanocine analogs were synthesized and characterized at the University by the Licensee's founders. Indanocine displayed potent anti-proliferative activity when tested against a multitude of cancer cell lines at the NCI. These compounds differ from many clinically used drugs that block cell division in that they are active against multi-drug resistant cells and selectively kill non-dividing malignant cells. Anti-tumor activity of SDX-103 analogs has been observed in preliminary animal studies.

Field of Use
SDX-101 is covered by two use patents in the U.S. that prohibit third parties from using etodolac and etodolac analogs to treat CLL and NHL and R-etodolac and R-etodolac analogs to treat leukemias. These use patents expire in 2019. In the U.S. and selected foreign countries, the Licensee is pursuing additional use patents for etodolac, R-etodolac and etodolac analogs as well as composition of matter patents for etodolac analogs in the U.S. and in selected foreign countries.  SDX-102 and assay methods were covered by two use patents in the U.S. that prohibit third parties from using an assay to measure MTAP status in a patient and then treating with an adenyl succinate synthetase inhibitor such as alanosine. These patents expired in 2013. SDX-102 is also covered by a patent in the U.S. that prohibits third parties from treating multiple drug resistance in MTAP-deleted tumors using an adenine synthesis inhibitor, such as l-alanosine. A patent application covering an assay method and monoclonal antibody for determining the presence or absence of MTAP is currently pending. Similar applications are being pursued or have issued in selected foreign countries.

IPSCIO Record ID: 359490

License Grant
The Chinese Licensor and Licensee collaborated on the sale for ORPATHYS® (savolitinib) in China.  Licensor is responsible for the clinical development, marketing authorization, manufacturing and supply of ORPATHYS® in China, while Licensee is responsible for its commercialization on China sales.
License Property
ORPATHYS® (savolitinib), an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase.

ORPATHYS® is an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”) that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations) or gene amplification.

The Phase II trial is an open-label, two-cohort, multi-center study to evaluate the efficacy, safety and pharmacokinetics (“PK”) of ORPATHYS® in locally advanced or metastatic GC or GEJ patients whose disease progressed after at least one line of standard therapy.

Field of Use
Field of use is for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”).

IPSCIO Record ID: 26237

License Grant
The agreement granted exclusive development and commercialization rights to the Licensor's fully human, immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014 for the greater Chinese market.
License Property
The mAb is novel, proprietary, and fully human. The Licensor is currently developing production quality cell lines for their anti-PD-L1 antibody, STI-A1010, which will lay the foundation for Investigational New Drug, or IND, -enabling studies in the U.S. in 2014. The Licensor anticipates that a Phase I clinical trial for their lead candidate anti-PD-L1 antibody could be initiated in 2015.  The mAb's are derived from the Licensor's proprietary G-MAB® library platform and chosen based on cancer targets.

Patent Antigen binding proteins that bind PD-L1

Field of Use
The individual mAbs discovered from the Licensor's library potentially give a multitude of therapeutic options to target and attack cancer cells. This could be either directly, such as (i) recruitment of immune effector functions, including, but not limited to, antibody-dependent cellular cytotoxicity, or ADCC, or (ii) antagonistic suppression of cellular signaling processes required for cancer proliferation and metastasis; or indirectly, via modulation host biology, such as (a) enhancement of immune activity in the tumor, or (b) normalization of the tumor microenvironment, including anti-angiogenesis for cutting off blood supplies to the tumor.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.